A protein that normally deposits mineralized calcium in tooth enamel may also be responsible for calcium deposits in the back of the eye in people with dry age-related macular degeneration (AMD), according to a study from researchers at the National Eye Institute (NEI).
Johns Hopkins Medicine scientists say they have successfully turned back the biological hands of time, coaxing adult human cells in the laboratory to revert to a primitive state, and unlocking their potential to replace and repair damage to blood vessels in the retina caused by diabetes. The findings from this experimental study, they say, advance regenerative medicine techniques aimed at reversing the course of diabetic retinopathy and other blinding eye diseases.
An artificial intelligence (AI) device that has been fast-tracked for approval by the Food and Drug Administration may help identify newborns at risk for aggressive posterior retinopathy of prematurity (AP-ROP). AP-ROP is the most severe form of ROP and can be difficult to diagnose in time to save vision.
Promising intracellular protein-based therapeutics have been of limited use due to the difficulty of delivery into diseased cells. Now bioengineers have developed nanoparticles that can deliver these therapeutics to their targets—avoiding degradation and toxic interactions with healthy tissues.
With $9.7 million in funding from the National Eye Institute, researchers at the University of Illinois at Chicago will study the impact of chronic eye disease among Latinos.
In a recent study using mice, lab-grown human retinal cells and patient samples, Johns Hopkins Medicine scientists say they found evidence of a new pathway that may contribute to degeneration of the light sensitive tissue at the back of the eye. The findings, they conclude, bring scientists a step closer to developing new drugs for a central vision-destroying complication of diabetes that affects an estimated 750,000 Americans.
Researchers at the National Eye Institute used artificial intelligence to evaluate stem cell-derived “patches” of retinal pigment epithelium tissue for implanting into the eyes of patients with age-related macular degeneration, a leading cause of blindness.
Results from a clinical trial funded by the National Eye Institute (NEI) show that while vision therapy can successfully treat convergence insufficiency (CI) in children, it fails to improve their reading test scores.
Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodies, or ACPAs, in human tear fluid. They are also the first to demonstrate that patients with dry eye disease experienced reduced signs and symptoms of the condition in response to a new eye drop treatment -- made from pooled human antibodies -- that targets ACPAs.
Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis
Showing results
1–10 of 10
RSS Feeds by Section